Hemab Therapeutics Holdings, Inc. (COAG)
41.45
+1.03
(+2.55%)
USD |
NASDAQ |
Oct 30, 16:00
41.45
0.00 (0.00%)
After-Hours: 20:00
Hemab Therapeutics Holdings Enterprise Value : 1.480B for Oct. 30, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 30, 2026 | 1.480B |
| October 29, 2026 | 1.431B |
| October 28, 2026 | 1.342B |
| October 27, 2026 | 1.337B |
| October 26, 2026 | 1.226B |
| October 23, 2026 | 1.150B |
| October 22, 2026 | 1.170B |
| October 21, 2026 | 1.194B |
| October 20, 2026 | 1.139B |
| October 19, 2026 | 1.042B |
| October 16, 2026 | 948.00M |
| October 15, 2026 | 1.062B |
| October 14, 2026 | 941.93M |
| October 13, 2026 | 935.39M |
| October 12, 2026 | 962.94M |
| October 09, 2026 | 1.020B |
| October 08, 2026 | 986.30M |
| October 07, 2026 | 884.01M |
| October 06, 2026 | 868.60M |
| October 05, 2026 | 972.28M |
| October 02, 2026 | 996.57M |
| October 01, 2026 | 994.24M |
| September 30, 2026 | 983.96M |
| September 29, 2026 | 1.066B |
| September 28, 2026 | 1.090B |
| Date | Value |
|---|---|
| September 25, 2026 | 1.166B |
| September 24, 2026 | 1.212B |
| September 23, 2026 | 1.259B |
| September 22, 2026 | 1.330B |
| September 21, 2026 | 1.317B |
| September 18, 2026 | 1.467B |
| September 17, 2026 | 1.469B |
| September 16, 2026 | 1.457B |
| September 15, 2026 | 1.417B |
| September 14, 2026 | 1.434B |
| September 11, 2026 | 1.384B |
| September 10, 2026 | 1.406B |
| September 09, 2026 | 1.622B |
| September 08, 2026 | 1.625B |
| September 04, 2026 | 1.618B |
| September 03, 2026 | 1.616B |
| September 02, 2026 | 1.631B |
| September 01, 2026 | 1.600B |
| August 31, 2026 | 1.679B |
| August 28, 2026 | 1.638B |
| August 27, 2026 | 1.855B |
| August 26, 2026 | 1.841B |
| August 25, 2026 | 1.862B |
| August 24, 2026 | 1.723B |
| August 21, 2026 | 1.840B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.229B |
| Oncolytics Biotech, Inc. | 49.35M |
| Sangamo Therapeutics, Inc. | 39.80M |
| Sarepta Therapeutics, Inc. | 2.224B |
| Anixa Biosciences, Inc. | 92.94M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.15M |
| Total Expenses (Quarterly) | 24.15M |
| EPS Diluted (Quarterly) | -0.5171 |
| Earnings Yield | -3.84% |
| Normalized Earnings Yield | -3.840 |